Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy

Table 3

Locoregional recurrence, distant metastases, and overall survival rates according to pathologic factors.

Variable	Patient	Overall survival		LRR free survival		DM free survival
		Deaths	𝑃 value	LRR	𝑃 value	DM	𝑃 value
Multiple foci
No	99	40		18		46
Yes	71	32	0.60	8	0.28	40	0.19
Pathologic T
pTx/pTis	14	8		3		8
pT1	26	5		0		7
pT2	75	29		8		38
pT3	18	10		5		11
pT4	37	20	0.04	10	0.015	22	0.13
Pathologic N
pN0	20	3		2		3
pN1	63	27		9		28
pN2	52	26		12		33
pN3	35	16	0.026	3	0.12	22	0.0002
Stage
0	3	2		1		2
I	6	0		0		0
IIa	25	7		3		7
IIb	25	9		4		9
IIIa	43	20		6		27
IIIb	39	18		8		21
IIIc	29	16	0.049	4	0.76	20	0.0006
Histology
Ductal invasive	118	52		19		59
Lobular invasive	36	13		1		19
Others	16	7	0.85	6	0.008	8	0.94
Pathologic skin involvement
Absent	136	56		16		67
Present	34	16	0.78	10	0.018	19	0.83
LVI
Absent	101	38		14		44
Present	69	34	0.19	12	0.35	42	0.044
Nuclear grading*
G1	11	4		0		5
G2	54	17		3		25
G3	80	40	0.18	16	0.024	44	0.52
Ki 67 index
<20	117	48		21		57
≥20	53	24	0.15	5	0.34	29	0.09
ER status
Negative	64	35		10		37
Positive	106	37	0.015	16	0.99	49	0.20
PgR status
Negative	83	36		13		41
Positive	87	36	0.83	13	0.87	45	0.83
Extracapsular extension
Absence	115	37		13		48
Presence	55	35	0.0007	13	0.035	38	0.003
Total	170	72		26		86

∗Some data are missing.
LRR: locoregional recurrence; DM: distant metastases; PMRT: postmastectomy radiotherapy; LVI: lymph vascular invasion; ER: estrogen receptors; PgR: progesterone receptors.